Dataset from A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00006462
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
创建时间：
2026-03-01
